Financial Performance - In Q3 2024, the company achieved a revenue of 957 million CNY, a year-on-year increase of 59.73% [5] - The net profit attributable to shareholders was 407 million CNY, reflecting a growth of 101.38% [5] - For the first three quarters of 2024, total revenue reached 2.533 billion CNY, up 87.97% year-on-year [5] - The net profit attributable to shareholders for the same period was 1.063 billion CNY, a significant increase of 158.99% [5] Product Performance - The growth in performance is primarily driven by the continued sales increase of the core product, Furmetinib, which was included in the national medical insurance directory [6] - Sales expenses for the first three quarters were 988 million CNY, with a sales expense ratio of 39.01% [6] - The company has introduced new products, including KRAS G12C inhibitor and SHP2 inhibitor, expanding its oncology pipeline [6] Clinical Research and Development - Furmetinib has shown promising clinical data, with an overall response rate (ORR) of 81.8% in a global Phase Ib study for EGFR PACC mutation non-small cell lung cancer (NSCLC) patients [7] - The company is actively exploring combination therapies with Furmetinib to enhance treatment efficacy [8] - A global multi-center exploratory study for Furmetinib in treating EGFR PACC mutation NSCLC is underway, with over 160 patients enrolled [11] Market Expansion and Strategy - The company anticipates steady growth in new patient numbers due to the inclusion of Furmetinib in the national medical insurance reimbursement list [10] - The sales team is continuously expanding and optimizing, increasing the number of hospitals and doctors covered [11] - The company is also pursuing IND plans for new products, including a new generation of EGFR oral small molecule inhibitors and KRAS G12D inhibitors [17]

证券代码：688578 证券简称：艾力斯 公告编号：2024-031 上海艾力斯医药科技股份有限公司关于公司股东 减持股份结果暨权益变动达 1%的提示性公告 股东上海艾祥企业发展中心（有限合伙）、上海艾耘企业发展中心（有限合 伙）保证向上海艾力斯医药科技股份有限公司提供的信息不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 公司董事会及全体董事保证公告内容与上述股东提供的信息一致。 本次权益变动情况 本次权益变动不会导致公司控股股东及实际控制人发生变化，不会影响公 司的治理结构及持续经营。本次权益变动后，员工持股平台合计持有公司股份数 42,701,022 股，占公司总股本 9.49%。 1 | | 股东名称 | 持股数量（股） | 持股比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | --- | | 第一组 | 上海艾祥、上海艾耘 | 47,201,022 | 10.49% | 公司实际控制人杜锦豪先生及其夫人祁菊女 | | | 杜锦豪 | 10,800,001 | 2.40% | 士合计持有上海乔可企业发展有限公司 100% ...

对三季度的情况做一个汇报2014年第三季度公司实现营业收入9.57亿元较去年同期增长59.73%扣费前后的净利润分别为4.07亿元和3.64亿元分别同比增长101%和85%公司前三季度实现营业收入25.33亿元同比增长88% 扣费前后金利润分别为10.63亿元和10.11亿元分别同比增长159%和166%上述的业绩增长则寓于公司产品销售的持续放量宏美提尼自去年底续约进入一保后通过我们专业的推广市场占有率稳步提升同时公司对费用的管控也高度重视2023年前三季度公司销售费用为9.88亿元销售费用率持续降至39.01% 同时管理费用1.09亿元占比降低至4.31%除了业绩表现外公司第三季度在产品引进和产品研发上也颇有建树在8月份公司引进了KROPS CCIC一直级格莱雷塞和SHIP2一直级进一步拓展了公司在肿瘤领域管线的布局包括肺癌、胰腺癌以及节肢肠癌等在9月格莱雷塞联合希佗西丹康用于晚期精致节肢肠癌的适应症 获得了CDE突破性治疗品统的认定除此之外公司的ASP2303也在9月获批临床案例用于携带EGFR-C4GS晚期肺癌患者的治疗在9月 银美提尼丹药针对PEG突变一线治疗的全期全球1B7临床科学研究永登WCLC大 ...

对三季度的情况做一个汇报2014年第三季度公司实现营业收入9.57亿元较去年同期增长59.73%扣费前后的净利润分别为4.07亿元和3.64亿元分别同比增长101%和85%公司前三季度实现营业收入25.33亿元同比增长88% 扣费前后金利润分别为10.63亿元和10.11亿元分别同比增长159%和166%上述的业绩增长则寓于公司产品销售的持续放量宏美提尼自去年底续约进入一保后通过我们专业的推广市场占有率稳步提升同时公司对费用的管控也高度重视2023年前三季度公司销售费用为9.88亿元销售费用率持续降至39.01% 同时管理费用1.09亿元占比降低至4.31%除了业绩表现外公司第三季度在产品引进和产品研发上也颇有建树在8月份公司引进了KROPS CCIC一直级格莱雷塞和SHIP2一直级进一步拓展了公司在肿瘤领域管线的布局包括肺癌、胰腺癌以及节肢肠癌等在9月格莱雷塞联合希佗西丹康用于晚期精致节肢肠癌的适应症 获得了CDE突破性治疗品统的认定除此之外公司的ASP2303也在9月获批临床案例用于携带EGFR-C4GS晚期肺癌患者的治疗在9月 银美提尼丹药针对PEG突变一线治疗的全期全球1B7临床科学研究永登WCLC大 ...

艾力斯（688578.SH） 化学制药 证券研究报告/公司点评报告 2024 年 10 月 25 日 Q3 收入利润双超预期，海外临床即将有进展 ——艾力斯三季报点评 | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------ ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥957 million, representing a year-on-year increase of 59.73%[2] - Net profit attributable to shareholders for Q3 2024 was ¥407 million, up 101.38% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥364 million, reflecting an 85.44% increase year-on-year[2] - For the first nine months of 2024, total revenue reached CNY 2.533 billion, an increase of 87.97% compared to the same period last year[13] - Total operating revenue for the first three quarters of 2024 reached CNY 2,533,480,109.53, a significant increase from CNY 1,347,801,762.83 in the same period of 2023, representing an increase of approximately 88.1%[16] - Net profit for the first three quarters of 2024 was CNY 1,062,948,077.37, compared to CNY 410,427,066.86 in the same period of 2023, marking an increase of about 158.5%[16] - The company reported a total comprehensive income of CNY 1,118,116,117.50 for the first three quarters of 2024, compared to CNY 412,056,257.48 in 2023, which is an increase of approximately 171.5%[18] - Basic and diluted earnings per share for the first three quarters of 2024 were both CNY 2.36, compared to CNY 0.91 in the same period of 2023, representing an increase of approximately 159.3%[18] Research and Development - Research and development expenses totaled ¥234 million in Q3 2024, a significant increase of 198.76% compared to the same period last year[3] - The ratio of R&D expenses to operating revenue increased by 24.41 percentage points to 11.36%[3] - Research and development expenses for the first three quarters of 2024 totaled CNY 207,670,593.28, up from CNY 191,351,163.78 in 2023, indicating a growth of approximately 8.5%[16] - The company signed a licensing and development agreement with JAKOS for exclusive rights to develop KRAS G12C inhibitor and SHP2 inhibitor in China, expanding its oncology pipeline[13] - The company received approval from the National Medical Products Administration to conduct clinical trials for AST2303, a new generation EGFR oral inhibitor targeting EGFR C797S mutation[13] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥5.43 billion, a 24.14% increase from the end of the previous year[3] - As of September 30, 2024, total assets amounted to CNY 5.433 billion, up from CNY 4.376 billion at the end of 2023[15] - The company's total liabilities as of September 30, 2024, were CNY 570 million, compared to CNY 394 million at the end of 2023[15] - The company's retained earnings rose significantly from CNY 229 million to CNY 908 million compared to the previous year[15] - The company’s capital reserve increased from CNY 3.175 billion to CNY 3.230 billion year-over-year[15] Cash Flow and Operating Activities - Cash flow from operating activities for the year-to-date period reached ¥1.24 billion, up 167.71% year-on-year[2] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 1,236,489,837.49, compared to CNY 461,873,407.41 in the same period of 2023, reflecting an increase of about 167.5%[19] - The company reported cash and cash equivalents of CNY 474,698,599.31 at the end of the third quarter of 2024, down from CNY 988,981,874.59 at the end of 2023, indicating a decrease of approximately 52.0%[19] - The cash and cash equivalents decreased from CNY 1.862 billion at the end of 2023 to CNY 717 million as of September 30, 2024[15] - The company received cash from sales and services amounting to CNY 2,791,421,304.47 in the first three quarters of 2024, compared to CNY 1,449,107,899.32 in the same period of 2023, an increase of approximately 92.7%[19] Strategic Initiatives - The company implemented cost reduction and efficiency improvement measures, contributing to a net profit increase[5] - The company plans to continue expanding its product offerings and market presence, particularly in the area of innovative drug development[6] Accounting and Reporting - The company has adopted new accounting standards starting in 2024, impacting the financial statements from the beginning of the year[20] - The third quarter report was officially announced on October 25, 2024[21]

特此公告。 上海艾力斯医药科技股份有限公司董事会 2024 年 10 月 10 日 证券代码：688578 证券简称：艾力斯 公告编号：2024-030 上海艾力斯医药科技股份有限公司 关于更换保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海艾力斯医药科技股份有限公司（以下简称"公司"）于近日收到中信证 券股份有限公司（以下简称"中信证券"）出具的《关于更换保荐代表人的函》。 中信证券作为公司首次公开发行股票并在科创板上市项目的保荐机构，原指定杨 沁先生、褚晓佳女士履行持续督导职责，持续督导期至 2023 年 12 月 31 日止， 由于公司首次公开发行的募集资金尚未使用完毕，中信证券将对募集资金使用情 况继续履行持续督导义务。现因褚晓佳女士工作调整，不再负责对公司的持续督 导工作。为保证持续督导工作有序进行，中信证券现委派陈溦先生（简历见附件） 接替褚晓佳女士担任公司的保荐代表人，继续履行持续督导职责。本次变更后， 公司首次公开发行股票并在科创板上市项目的保荐代表人为杨沁先生和陈溦先 生。 本次变更 ...

本次电话会议服务于中泰证券正式签约 中泰证券授权请勿对外传播本次会议的内容包括但不限于视频音频文字记录内容等信息感谢您的理解与配合中泰证券对违反上述要求的行为保留追究法律责任的权利市场有风险投资需谨慎本会议信息仅供参考不代表任何投资建议本公司不对任何人因使用本会议中的信息所引致的任何损失不担任何责任 好的 尊敬的各位投资者 大家晚上好 我是中菜一号曹乐韵再次感谢大家的时间我们今天是整个肺癌专题深度报告的第二个我们也精选了几个我们现在无论是从基本的发展上还是从编辑判断上或者从预期差上非常看好的看好最后去实质走向的几家公司今天是第二家爱丽丝 正如我这个PPT第一章给大家展示这样我觉得在讲深度报告之前还是跟大家聊聊天我今天这个引言标题非常鲜明我认为做mebetter是比first in class更好的生意这个无论对于中国要紧还是对于外国要紧论对于中国市场还是全球市场从今年站在2024年的视角我认为都是这样子的 理由举几个例子吧曾经的这个first class取得到非常成功的这些产品也是其实就我个人看来其实这些产品在当年上市的时候他几乎不需要做什么这个销售上的这种刺激几乎是可以几乎是可以说患者呀医生呀来主动找你买药 ...

Investment Rating - The report assigns a "Buy" rating to the company [3]. Core Views - The company has demonstrated strong revenue and profit growth driven by effective commercialization strategies, with significant evidence supporting a long product lifecycle [2][3]. - The company’s revenue is expected to continue growing, with projections indicating a revenue increase from 791 million in 2024E to 5,264 million by 2026E, reflecting a compound annual growth rate (CAGR) of 20.8% [3]. - Net profit is forecasted to rise from 131 million in 2024E to 1,907 million by 2026E, with a CAGR of 21.5% [3]. - The company is positioned to capitalize on the growing market for lung cancer treatments, particularly with its product, Furmetinib, which is expected to achieve peak sales exceeding 5.5 billion [3][33]. Summary by Sections Company Overview - The company, Shanghai Ailis Pharmaceutical Technology Co., Ltd., was established in March 2004 and focuses on research, production, and marketing in the pharmaceutical sector, particularly in lung cancer treatments [23][25]. Financial Performance - The company reported a revenue of 20.18 billion in 2023, a year-on-year increase of 155%, and a net profit margin of 31.9% [25][26]. - The sales expense ratio has decreased to 45.6% in 2023, contributing to improved profitability [25][28]. Product Pipeline - The company has a robust pipeline, including self-developed products and licensed products, enhancing its market position [29][30]. - Recent agreements for commercialization rights of RET inhibitors and KRAS inhibitors are expected to further strengthen the product lineup [29][30]. Market Potential - The report highlights the increasing incidence of lung cancer in China, with 1.06 million new cases reported in 2022, indicating a significant market opportunity for targeted therapies [33][42]. - The company’s product, Furmetinib, has been approved for both first-line and second-line treatments for non-small cell lung cancer (NSCLC) and is included in the national medical insurance [42][43]. Competitive Landscape - The company’s third-generation EGFR-TKI, Furmetinib, is positioned favorably against competitors, showing superior progression-free survival (PFS) rates in clinical trials [35][44].

| 药品名称 | AST2303 片 | | --- | --- | | 注册分类 | 1 类 | | 申请人名称 | 上海艾力斯医药科技股份有限公司 | | 受理号 | CXHL2400714、CXHL2400715 | | 通知书编号 | 2024LP02152、2024LP02153 | | 适应症 | 本品拟用于携带 EGFR C797S 突变的晚期非小细胞肺癌成人患者 | 证券代码：688578 证券简称：艾力斯 公告编号：2024-029 上海艾力斯医药科技股份有限公司自愿披露 关于 AST2303 片获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海艾力斯医药科技股份有限公司（以下简称"公司"）于近日收到国家药 品监督管理局（以下简称"国家药监局"）核准签发的《药物临床试验批准通知 书》，同意 AST2303 片在携带 EGFR C797S 突变的晚期非小细胞肺癌成人患者中 开展临床试验。现将相关情况公告如下： 是与公司已上市的第三代 EGFR 抑制剂伏美替 ...